|
|
|
|
|
|
|
M T Wed Th F |
|
2 September, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
As President Trump pushes the Senate to confirm Heidi Overton as the next FDA commissioner before the November elections, her latest financial disclosure report likely won't tip the scale in either direction. Overton made about $300,000 from the America First Policy Institute in 2024 and roughly $40,000 for consulting on the Trump-Vance transition, before bringing in about $155,000 in salary as a domestic policy advisor to Trump beginning in January 2025. She didn't disclose any investments in health care or biopharma companies. |
|
|
|
Zachary Brennan |
Senior Editor, Endpoints News
@ZacharyBrennan
|
|
|
|
|
|
|
by Nicole DeFeudis
|
Many researchers believe cancer cell therapies called CAR-Ts could shift the treatment paradigm for patients with autoimmune disease. But three recently disclosed deaths in Novartis’... | |
|
|
|
|
|
|
by Max Bayer
|
Top FDA leaders are doubling down on clinical trial oversight measures to ensure that research data generated outside the US are adequate, as lawmakers and... | |
|
|
|
|
|
|
by Zachary Brennan
|
Asha Das, director of the FDA biologics center's office of clinical evaluation, overruled the agency's review team in granting an accelerated approval to Replimune's melanoma... | |
|
|
|
|
|
| . |
 |
|
|
|
by Ryan Cross
|
The deaths of two children who received CRISPR therapies in China have rattled scientists who work on similar genetic medicines in the US, adding new... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
Plus, news about Regeneron, Novocure, Jazz's Ziihera, BioMarin, Ascendis, AstraZeneca, Hutchmed and TScan Therapeutics. Another road bump for Tavneos: The Medicines and Healthcare products... | |
|
|
|
|
|
